Back to Screener

Healthcare

Beam Therapeutics Inc.(BEAM)

Live Price

Offline

$33.93

+0.09% today

1Y Change

+93.70%

Window

Jun 26, 2025 โ†’ Jun 23, 2026

Market Cap
$2.97B
Revenue Growth
+120.0%
EPS Growth
+82.3%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 26, 2025 โ†’ Jun 23, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Beam Therapeutics Inc. (BEAM) is a Healthcare stock with a market cap of $2.97B. The stock last traded around $33.93 and up 93.7% across the available one-year price window (Jun 26, 2025 โ†’ Jun 23, 2026). Baseline metrics include revenue growth of +120.0%, EPS growth of +82.3%, a dividend yield of 0.0%. What stands out right now is revenue +120.0%, EPS +82.3%, free cash flow -1.1% with operating margin -274.6% and ROIC -27.4%. Valuation already assumes a fairly strong business story at price/sales 21.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BEAM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

BEAM vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

BEAM

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

BEAM Max Drawdown

-38.15%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for BEAM and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for BEAM

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.